Product Description
Cudetaxestat (BLD-0409) is a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis. (Sourced from: https://www.blademed.com/news/august-22-2022/)
Mechanisms of Action: Autotaxin Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Scleroderma, General *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Blade Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis
Phase 1: Healthy Volunteers|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Hepatitis, Chronic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B-0409-201 | P2 |
Unknown status |
Idiopathic Pulmonary Fibrosis |
2023-12-30 |
35% |
| B-0409-104 | P1 |
Completed |
Healthy Volunteers |
2021-12-16 |
28% |
| B-0409-103 | P1 |
Completed |
Healthy Volunteers |
2021-09-17 |
70% |
| B-0409-102 | P1 |
Completed |
Healthy Volunteers |
2021-08-17 |
28% |